Antioxidant can lower the risk of second heart attack or stroke, finds a new study.
![Powerful Antioxidant Can Reduce the Risk of Second Heart Attack, Stroke Powerful Antioxidant Can Reduce the Risk of Second Heart Attack, Stroke](https://images.medindia.net/health-images/1200_1000/stable-angina.jpg)
‘Cells and platelets stick inside arteries and increase the risk of second heart attack. Apocynin, a potent antioxidant can decrease the plaque buildup in half and lowers this risk.
’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Heart attacks in mice caused inflammatory cells and platelets to more easily stick to the inner lining of arteries throughout the body and particularly where there was already plaque, according to the paper. ![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
As a result, these sticky cells and platelets caused plaque to become unstable and contribute to blood clots that led to another heart attack or stroke.
But the study found treating mice that had experienced a heart attack or stroke with the powerful antioxidant apocynin cut plaque buildup in half and lowered inflammation to pre-attack levels.
"Knowing that newer forms of antioxidants such as apocynin can lower the risk of a second heart attack or stroke gives us a new treatment to explore and could one day help reduce heart attacks and strokes," said the paper's corresponding author, Jonathan R. Lindner, M.D., a professor of cardiovascular medicine at the OHSU School of Medicine.
Lindner penned the research paper with colleagues from OHSU, Scripps Research Institute and Bloodworks NW.
Advertisement
This research could help explain why the recent Canakinumab Anti-inflammatory Thrombosis Outcomes Study, also known as the CANTOS clinical trial, found an anti-inflammatory drug already approved to treat juvenile arthritis also reduced the risk of a second heart attack in trial participants by 15 percent.
Advertisement
Source-Eurekalert